Author:
Brandi Giovanni,Tavolari Simona
Publisher
Springer International Publishing
Reference114 articles.
1. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31. https://doi.org/10.1111/liv.14095.
2. Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. J Transl Med. 2017;15(1):229. https://doi.org/10.1186/s12967-017-1328-z.
3. Yamaguchi N, Morioka H, Ohkura H, Hirohashi S, Kawai K. Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J Natl Cancer Inst. 1985;75(1):29–35.
4. Homma S, Nagamori S, Fujise K, Yamazaki K, Hasumura S, Sujino H, Matsuura T, Shimizu K, Kameda H, Takaki K. Human bile duct carcinoma cell line producing abundant mucin in vitro. Gastroenterol Jpn. 1987;22(4):474–9. https://doi.org/10.1007/bf02773816.
5. Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl). 1988;188(5):367–75. https://doi.org/10.1007/bf01851205.